Quick Answer
UroGen Pharma Ltd. reported Net Income of -$153.49 million for fiscal year 2025.
UroGen Pharma Ltd. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$153.49M | -21.0% |
| 2024 | -$126.87M | -24.1% |
| 2023 | -$102.24M | +6.9% |
| 2022 | -$109.78M | +0.9% |
| 2021 | -$110.82M | +13.7% |
| 2020 | -$128.48M | -22.2% |
| 2019 | -$105.15M | -39.0% |
| 2018 | -$75.66M | -278.3% |
| 2017 | -$20.00M | -930.4% |
| 2016 | -$1.94M | +84.7% |
| 2015 | -$12.69M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$33.35M | -40.9% | +33.2% |
| June 30, 2025 | -$49.94M | -49.5% | -13.9% |
| March 31, 2025 | -$43.84M | -35.8% | -85.2% |
| September 30, 2024 | -$23.67M | -8.2% | +29.1% |
| June 30, 2024 | -$33.40M | -38.4% | -3.5% |
| March 31, 2024 | -$32.29M | -6.9% | -47.6% |
| September 30, 2023 | -$21.88M | +15.3% | +9.4% |
| June 30, 2023 | -$24.14M | +9.6% | +20.1% |
- UroGen Pharma Ltd. showed a decrease of -21.0% in Net Income compared to the prior fiscal year.
- Over the 2015–2025 period, UroGen Pharma Ltd.’s net income has declined by 1109.7% (from -$12.69 million to -$153.49 million).
- The most recent figure is from UroGen Pharma Ltd.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: